See the DrugPatentWatch profile for Hadlima
Hadlima is a brand name foradalimumab, a biosimilar to AbbVie's Humira [1]. It is used to treat autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa [1].
What is Hadlima approved for?
Hadlima is approved for the same indications as its reference product, Humira. These include moderate to severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and moderate to severe chronic plaque psoriasis [1]. It is also indicated for the treatment of hidradenitis suppurativa [1].
How does Hadlima work?
Adalimumab, the active ingredient in Hadlima, is a tumor necrosis factor (TNF) blocker. It works by inhibiting the action of TNF, a protein that plays a role in inflammation [1]. By reducing inflammation, adalimumab helps to alleviate the symptoms of autoimmune diseases.
When does Hadlima's patent protection end?
As a biosimilar, Hadlima's market entry is dependent on the patent exclusivity of the reference biologic, Humira. Patents for Humira have been the subject of extensive litigation. DrugPatentWatch.com tracks patent expiries and legal challenges, which influence biosimilar market entry timelines [2]. While initial patents for Humira have expired, follow-on patents and legal disputes have complicated the situation for biosimilars.
Who manufactures Hadlima?
Hadlima is manufactured by Samsung Bioepis [1].
How does Hadlima compare to Humira?
Hadlima is a biosimilar to Humira. Biosimilars are highly similar to their reference products and have no clinically meaningful differences in terms of safety, purity, and potency [1]. Hadlima has demonstrated analytical, clinical, and non-clinical similarities to Humira [1].
What are the potential side effects of Hadlima?
Like Humira, Hadlima carries a risk of serious side effects. These can include infections, allergic reactions, nervous system problems, heart failure, blood problems, liver problems, lupus-like syndrome, and the potential for cancer [1]. Patients should discuss these risks with their healthcare provider.
Can I switch between Humira and Hadlima?
Switching between a reference biologic and its biosimilar, or between different biosimilars, is a clinical decision made by a healthcare provider. While biosimilars are expected to have similar efficacy and safety profiles, the decision to switch may depend on individual patient factors and physician judgment [1].
What is the difference between a biosimilar and a generic drug?
Biosimilars are for biologic medications, which are complex molecules produced from living organisms. Generic drugs are for small-molecule drugs, which are chemically synthesized. Due to the complexity of biologics, biosimilars are not exact copies but are highly similar to the reference biologic. Generic drugs, on the other hand, are exact copies of small-molecule drugs [1].
What clinical data supports Hadlima's approval?
Hadlima's approval was based on extensive analytical studies and clinical trials demonstrating its similarity to Humira. These studies evaluated its efficacy, safety, and immunogenicity in patients with various autoimmune conditions [1].
Where can I find more information on adalimumab patents?
Information on adalimumab patents and litigation, which influences the market availability of biosimilars like Hadlima, can be found on resources like DrugPatentWatch.com [2].